
Ask a doctor about a prescription for VALSARTAN VIATRIS 160 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Valsartan Viatris 160 mg film-coated tablets EFG
Read this package leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the package leaflet
Valsartan Viatris belongs to a class of medicines known as angiotensin II receptor antagonists, which help to control high blood pressure. Angiotensin II is a substance in the body that causes blood vessels to narrow, leading to an increase in blood pressure. Valsartan Viatris works by blocking the effect of angiotensin II. As a result, the blood vessels relax and blood pressure decreases.
Valsartan Viatris film-coated tablets can be used for three different conditions:
Among the symptoms of heart failure are difficulty breathing and swelling of the feet and legs due to fluid retention. This is because the heart muscle cannot pump blood with enough force to supply the body with the blood it needs.
Do not take Valsartan Viatris
If any of these apply to you, do not take Valsartan Viatris.
Warnings and precautions
Talk to your doctor or pharmacist before taking Valsartan Viatris
Talk to your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking valsartan. Your doctor will decide whether to continue treatment. Do not stop taking valsartan on your own.
Your doctor may check your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Valsartan Viatris”.
Patients may notice that this medicine has an unusual odor and/or taste. This is normal and characteristic of the active substance valsartan.
If any of these apply to you, tell your doctor before taking Valsartan Viatris.
Other medicines and Valsartan Viatris
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
The effect of treatment with Valsartan Viatris may be affected if you take it with certain other medicines. It may be necessary to change the dose, take other precautions, or in some cases, stop treatment with one of the medicines. This applies to both prescription and non-prescription medicines, especially:
In addition:
Your doctor may need to adjust your dose and/or take other precautions:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Before driving a vehicle, using tools, or operating machinery, or carrying out other activities that require concentration, make sure you know how Valsartan Viatris affects you. Like many other medicines used to treat high blood pressure, Valsartan Viatris may cause dizziness and affect your ability to concentrate.
Valsartan Viatris contains sodium
This medicine contains less than 23 mg (1 mmol) of sodium per dose, which is essentially “sodium-free”.
To get the best results and reduce the risk of side effects, follow exactly the instructions for taking this medicine given by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist again. People with high blood pressure often do not notice any symptoms of the disease; many feel normal. This makes it very important to keep your appointments with your doctor, even if you feel well.
Adult patients with high blood pressure:the usual dose is 80 mg once daily. In some cases, your doctor may prescribe higher doses (e.g., 160 mg or 320 mg). You may also take Valsartan Viatris in combination with another medicine (e.g., a diuretic).
Use in children and adolescents (6 to less than 18 years) with high blood pressure:in patients who weigh less than 35 kg, the recommended dose is 40 mg of valsartan once daily. In patients who weigh 35 kg or more, the usual starting dose is 80 mg of valsartan once daily. In some cases, your doctor may prescribe higher doses (the dose can be increased to 160 mg and up to a maximum of 320 mg).
In children who have difficulty swallowing tablets, it is recommended to administer valsartan oral solution.
Adult patients after a recent heart attack:after a heart attack, treatment is usually started at 12 hours, normally with a low dose of 20 mg, given twice daily. The 20 mg dose is obtained by dividing the 40 mg tablet. Your doctor will gradually increase this dose over several weeks to a maximum of 160 mg twice daily. The final dose will depend on your individual tolerance.
Valsartan Viatris can be given with other treatments for heart attack, and your doctor will decide which treatment is suitable for you.
Adult patients with heart failure:treatment is usually started with 40 mg twice daily. Your doctor will gradually increase the dose over several weeks to a maximum of 160 mg twice daily. The final dose will depend on your individual tolerance.
Valsartan Viatris can be given with other treatments for heart failure, and your doctor will decide which treatment is suitable for you.
You can take Valsartan Viatris with or without food. Swallow Valsartan Viatris with a glass of water.
Take Valsartan Viatris at about the same time each day.
The tablet can be divided into equal doses.
If you take more Valsartan Viatris than you should
If you feel a strong dizziness and/or fainting, contact your doctor immediately and lie down.
In case of overdose or accidental ingestion, contact your doctor or pharmacist, or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken. Bring the package and remaining tablets with you.
If you forget to take Valsartan Viatris
Try to take Valsartan Viatris daily as prescribed. However, if you miss a dose, do nottake a double dose to make up for the missed doses. Simply return to your regular schedule.
If you stop taking Valsartan Viatris
If you stop taking Valsartan Viatris, your condition may worsen. Do not stop taking the medicine unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Stop taking this medicine and consult your doctor or visit the emergency department of the nearest hospital if you experience any of the following adverse effects:
Uncommon(may affect up to 1 in 100 people)
Frequency not known(cannot be estimated from available data)
Other adverse effects:
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Very rare(may affect up to 1 in 10,000 people)
Frequency not known(cannot be estimated from available data)
The frequency of some adverse effects may vary depending on your condition. For example, certain adverse effects such as dizziness and reduced kidney function were observed less frequently in adult patients treated with high blood pressure than in adult patients treated for heart failure or after a recent heart attack.
The adverse effects in children and adolescents are similar to those observed in adults.
Reporting adverse effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the box after CAD or EXP. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE Point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Valsartan Viatris
The active ingredient is valsartan. Each tablet contains 160 mg of valsartan.
The other components are: microcrystalline cellulose, crospovidone, povidone, sodium croscarmellose, anhydrous colloidal silica, magnesium stearate.
The coating includes hypromellose (E-464), titanium dioxide (E-171), macrogol, vanillin, yellow iron oxide (E-172), black iron oxide (E-172), and red iron oxide (E-172).
Appearance of the Product and Package Contents
Valsartan Viatris 160 mg film-coated tablets are yellow/dark yellow, oval, biconvex, beveled, marked with the inscription "M" on the left side of the score line on one side and "VN 3" on the other side of the tablet.
The score line is used to divide the tablet into two equal doses.
Valsartan Viatris tablets are dispensed in blisters of 7, 10, 14, 28, 30, 56, 90, 98, 100 tablets, in a multiple package of 98 tablets which consists of 2 cartons (each containing 49 tablets), in HDPE bottles containing 56, 98, 500, and 1000 tablets, and HDPE bottles with desiccant containing 28, 30 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturers
McDermott Laboratories Limited trading as Gerard Laboratories
35/36 Baldoyle Industrial Estate
Grange Road, Dublin 13
Ireland
or
Mylan Hungary Kft.
H-2900 Komárom
Mylan utca 1
Hungary
or
Mylan Germany GmbH
Zweigniederlassung Bad Homburg Benzstrasse 1
61352 Bad Homburg v. d. Höhe
Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the Member States of the European Economic Areaand in the United Kingdom (Northern Ireland)with the following names:
GermanyValsartan dura 160 mg Filmtabletten
SpainValsartán Viatris 160 mg film-coated tablets EFG
FranceValsartan Viatris 160 mg, sécable film-coated tablet
IrelandValsartan Viatris 160 mg
ItalyValsartan Mylan Generics 160 mg
NetherlandsValsartan Viatris 160 mg filmomhulde tabletten
PortugalValsartan Mylan
United Kingdom(Northern Ireland)Valsartan Film-coated Tablets 160 mg
Date of the last revision of this prospectus:January 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/
The average price of VALSARTAN VIATRIS 160 mg FILM-COATED TABLETS in November, 2025 is around 16.3 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for VALSARTAN VIATRIS 160 mg FILM-COATED TABLETS – subject to medical assessment and local rules.